Rekombinanter IL2RA (Daclizumab Biosimilar) Antikörper

Produktnummer ABIN7487796

Produktdetails anti-IL2RA (Daclizumab Biosimilar) Antikörper

Target: IL2RA (Daclizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Mammalian Cells

Klonalität: Monoklonal

Konjugat: Dieser IL2RA (Daclizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA

Verwendungszweck: Daclizumab Biosimilar - Anti-IL2RA mAb

Produktmerkmale: Antibody Type: IgG1-kappa

Güteklasse: Research Grade

Isotyp: IgG1 kappa

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS pH 7.5

Lagerung: -80 °C

Informationen zur Lagerung: store at -80°C

Details zu IL2RA (Daclizumab Biosimilar)

Target: IL2RA (Daclizumab Biosimilar)

Abstract: IL2RA (Daclizumab Biosimilar) Produkte

Synonyme: CD25 antikoerper, IDDM10 antikoerper, IL2R antikoerper, TCGFR antikoerper, interleukin 2 receptor subunit alpha antikoerper, IL2RA antikoerper

Substanzklasse: Biosimilar

Hintergrund: BIIB019,DAC HYP
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

CAS-Nummer: 152923-56-3